Αρχική World News New Technology System Allows Patients To Get A Mammogram And Biopsy In...

New Technology System Allows Patients To Get A Mammogram And Biopsy In The Same Visit

The FDA has approved a healthcare industry first: a system that allows for breast biopsies to be performed in the same room with the same equipment as a mammogram.Called the Pristina Serena Bright, the system uses contrast-enhanced mammography to pinpoint any suspicious areas. Then, if a patient has a lesion that looks problematic enough to be biopsied, that procedure can be performed immediately in the same room with the same equipment and the same staff.The entire system reduces how much time a patient spends undergoing testing, how much time they spend waiting, and offers less overall discomfort.Here’s how it works.Photo: YouTube/GE HealthcareThe Serena Pristina is the brainchild of GE Healthcare and combines different technologies they’ve created. The mammogram component uses SenoBright CESM (contrast-enhanced spectral mammography), which is similar to an MRI but more accurate. (The company calls it a “next level mammogram.”)This type of mammogram is especially helpful for women with dense breasts. Dense breast tissue can often show up as white on traditional mammograms and make it difficult to discern any cancerous areas. In CESM, an iodinated contrast agent in injected into the patient (similar to what is done in an MRI), and cancerous tissue absorbs the liquid and is highlighted in the films that are taken. This makes any problematic areas much clearer.The healthcare team can access the breast from different angles, including the side, which reduces the need for repositioning and adjusting the breast tissue (and results in less discomfort for the patient).The breast exam using CESM is usually completed in less than seven minutes. The images are immediately available to a radiologist, who can then review the films and assess if any areas need a biopsy.Photo: YouTube/GE HealthcareIf needed, a breast biopsy can be done in less than 15 minutes. The system has a laser guide that precisely targets where the anesthesia and biopsy needle need to go. There is no guesswork, and no waiting.“The waiting list for MRI-guided biopsy can be as long as several weeks,” said Dr. Rodrigo Alcantara, Head of Breast Imaging Section at Hospital del Mar in Spain. “This new mammography-guided biopsy techniques allows for a comfortable experience and provides women with answers quickly.”Photo: YouTube/GE HealthcareReducing time spent undergoing procedures and awaiting results can not only allow for a quicker diagnosis and treatment plan, but it also greatly reduces a patient’s anxiety.“Now more than ever, it is critical we put the comfort of patients first and get them answers as fast as possible. We are proud to announce this FDA clearance during a time our customers need this type of innovation the most,” said President and CEO of Women’s Health at GE Healthcare, Agnes Berzsenyi. “We look forward to bringing this technology to the market in the upcoming months and hope it can help improve breast cancer outcomes for women during this time of uncertainty.”Learn more about the Pristina Serena in this video.Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and Bladder Cancer

The 2020 European Society for Medical Oncology (ESMO) Virtual Congress was held online from September 19 to September 21. In this podcast, Neeraj Agarwal,...

The UK Government’s spending review: Time to invest in the future of cancer care

This autumn, the chancellor Rishi Sunak will go to Parliament and set out the UK Government’s spending priorities in the Comprehensive Spending Review...

FDA Extends Approval of Pembrolizumab for Classical Hodgkin Lymphoma

On 14 October 2020, the US Food and Drug Administration (FDA) extended the approval of pembrolizumab (KEYTRUDA®, Merck Sharp & Dohme Corp.) for the...

31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During the Pandemic

The COVID-19 pandemic has been a scary and difficult thing for most of the world, and it’s important to keep safety protocols in place...

For Esophageal Cancer, Immunotherapy Likely to Play Larger Role

October 19, 2020, by NCI Staff An esophagram using barium contrast shows the esophagus. Credit: iStock Immunotherapy may become part of early treatment for some people with...

Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is Feasible

Targeted therapy recommendations can be made based on the molecular profiles of tumour samples from patients with metastatic malignant mesothelioma (MM) according to findings...